Edition:
India

TG Therapeutics Inc (TGTX.OQ)

TGTX.OQ on NASDAQ Stock Exchange Capital Market

7.70USD
17 Nov 2017
Change (% chg)

$-0.60 (-7.23%)
Prev Close
$8.30
Open
$8.30
Day's High
$8.30
Day's Low
$7.65
Volume
292,824
Avg. Vol
269,115
52-wk High
$15.35
52-wk Low
$4.10

Select another date:

Wed, Nov 8 2017

BRIEF-TG Therapeutics qtrly net loss per common share $0.48

* TG therapeutics, inc. Provides business update and reports third quarter 2017 financial results

BRIEF-TG Therapeutics Inc gives results from phase 2 multicenter trial of TG-1101

* TG Therapeutics Inc - ‍announced results from phase 2 multicenter trial of TG-1101 (ublituximab) in relapsing forms of multiple sclerosis​

BRIEF-TG Therapeutics announces completion of full enrollment in UNITY-CLL phase 3 trial

* TG Therapeutics announces completion of full enrollment in the UNITY-CLL phase 3 trial

BRIEF-TG Therapeutics announces completion of target enrollment

* TG Therapeutics announces completion of target enrollment in the unity-CLL phase 3 trial

BRIEF-TG Therapeutics announces successful outcome from first pre-planned interim analysis

* TG Therapeutics Inc announces successful outcome from the first pre-planned interim analysis by independent DSMB of the DLBCL cohort in the unity-NHL PHASE 2B trial

BRIEF-TG Therapeutics Q2 loss per share ‍$0.45​

* Tg therapeutics Inc provides business update and reports second quarter 2017 financial results

BRIEF-TG therapeutics provides FDA update on multiple sclerosis study

* Announces special protocol assessment (spa) agreement with the FDA for a Phase 3 program of TG-1101 (ublituximab) for patients with multiple sclerosis (MS)

BRIEF-TG Therapeutics provides additional data from early-stage cancer drug study

* Tg therapeutics - triple combination of tg-1101, tgr-1202 and bendamustine was generally well-tolerated with only gr 3/4 event >10% being neutropenia

BRIEF-TG Therapeutics says follow-up data for combination of TGR-1202 plus Ibrutinib

* TG Therapeutics, Inc. Announces follow-up data for combination of TGR-1202 (umbralisib) plus ibrutinib in patients with relapsed or refractory cll and mcl at the 14th international conference on malignant lymphoma

BRIEF-TG Therapeutics gives follow-up data from chemo-free triple combination

* TG Therapeutics Inc Announces follow-up data from the chemo-free triple combination of TG-1101, TGR-1202, and Ibrutinib at the 53rd annual meeting of the American Society Of Clinical Oncology

Select another date: